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Since this recognition more than 20 years ago, the initial focus has been on the characterization of local inflammation within the atherosclerotic lesion. More recently systemic inflammation has come under increasing scrutiny as a contributing factor in plaque progression, rupture and thrombosis. 2 Elevated levels of the non-specific inflammatory marker high-sensitivity C-reactive protein (hs-CRP) and the inflammatory cytokine interleukin (IL)-6 have been shown to be associated with increased cardiovascular risk independent of cholesterol levels. 3 However, these associations do not demonstrate causality. The recently published Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) is the first clinical study to show that modulation of systemic inflammation reduces cardiovascular events independently of low-density lipoprotein cholesterol (LDL-C) levels. 4 Canakinumab is a monoclonal antibody against IL-1b, the primary circulating form of IL-1. A large body of experimental and clinical data indicates that IL-1 and its downstream inflammatory mediator IL-6 are important drivers of atherosclerosis. 3 The CANTOS trial studied patients with a prior myocardial infarction who had 'generally well-controlled levels' of LDL-C but elevated hs-CRP (2 mg/L) and thus might be considered to be at elevated inflammatory risk. Concomitant with the reduction in cardiovascular events, there was a dose-dependent reduction of hs-CRP levels and IL-6. Therefore, the CANTOS trial provides the first scientific evidence in patients that targeted modulation of a key inflammatory pathway in atherosclerosis reduces clinical events.
The clinical implications of this trial, however, are less clear. The overall effect was completely driven by a lower incidence of myocardial infarction and there was no effect on cardiovascular mortality. 5 In terms of side effects there were significantly more deaths from infection in those treated with canakinumab and the treatment comes at considerable cost: US$200,000 per year in the United States. 4, 5 Thus it is of paramount importance to identify those who may benefit from treatment with monoclonal antibodies against IL-1b.
In this issue of the journal Munkhaugen et al. describe a cross-sectional study that aims to identify the proportion of coronary heart disease patients who are at elevated inflammatory risk as defined by an hs-CRP level 2 mg/L. 6 The study included 971 patients without concomitant inflammatory disease and 378 (39%) who had an hs-CRP level 2 mg/L and thus were considered to have an increased inflammatory risk, while hs-CRP was <2 mg/L in 593 (61%) patients. Two modifiable risk factors were found to be independent predictors of increased inflammatory risk: daily smoking and higher body mass index. The majority of those with increased inflammatory risk had LDL-C levels 1.8 mmol/L. Equally important, the majority of those with hs-CRP <2 mg/L had LDL-C levels 1.8 mmol/L. Regarding the population as a whole, 76% had either a residual inflammatory risk, an LDL-C level that was not on target, or a combination of both. 6 Because not only LDL-C but also hs-CRP responds to cardiovascular risk management, these findings indicate that cardiovascular risk management needs to be improved in the majority of patients reported here. This is in concordance with a large literature that describes suboptimal cardiovascular risk management in patients with coronary and non-coronary atherosclerosis. 7, 8 Munkhaugen et al. suggest to improve cardiovascular risk management before considering anti-IL-1b treatment. 6 In CANTOS the median level of LDL-C was 82 mg/ dL ¼ 2.12 mmol/L in those treated with canakinumab. 4 Thus, in CANTOS, the LDL-C level was above target and there would appear to be room for improved lipid management. In the current study 12% of the total study population had hs-CRP 2 mg/L but were on target regarding their LDL-C. Would they be candidates for treatment with the anti-IL-1b antibody? The authors caution against this conclusion because among this subgroup there were 42 (36.5%) who were on low intensity statin therapy, indicating that there may have been room for further hs-CRP reduction through intensified lipid management. Indeed, intensive lipid management with a statin and ezetimibe has been shown to achieve both hs-CRP levels <2 mg/L and LDL-C <1.8 mmol/L. 9 In those who achieved both targets, the cardiovascular event rate was significantly lower than in those who achieved only one target or none at all. 9 Thus, it appears that a reduction of both hs-CRP and LDL-C is desirable and that this can be achieved with intensive lipid management. Moreover, it is becoming increasingly clear that LDL-C reductions to below 1.8 mmol/L convey incremental protection against cardiovascular events and that this can be done safely. 10, 11 Therefore, if hs-CRP remains 2 mg/L while LDL-C is 1.8 mmol/L, intensification of lipid management might be considered to bring hs-CRP below 2 mg/L. Within this context it is important to note that in CANTOS, canakinumab did not reduce LDL-C and thus may not be the optimal risk reduction strategy. Whether reduction of hs-CRP with canakinumab conveys additional clinical benefits over hs-CRP reduction achieved through lipid management remains an open question for now.
The current study was not designed to assess increased inflammatory risk. It is a post-hoc analysis of a cohort that was recruited to identify socio-demographic, medical and psychological factors that are associated with suboptimal cardiovascular risk management and cardiovascular events. 12 hs-CRP was not included in the original baseline assessment. Thus, the study may be underpowered to assess the extent of inflammatory risk.
Nevertheless, Munkhaugen et al. provide arguments to proceed with caution regarding the clinical introduction of anti-IL-1b therapy because they show that there is room for improvement of cardiovascular risk management in those with increased inflammatory risk. It is currently unclear which patients might benefit from anti-IL-1b treatment. A randomized comparison of intensive lipid management versus anti-IL-1b regarding effects on hs-CRP, LDL-C and clinical outcomes may identify those who will benefit most from either approach.
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